Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV, LLC consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Companies in the Foresite Capital Management IV portfolio as of the September 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Relay Therapeutics 20.5 $91M NEW 2.1M 42.59
Nurix Therapeutics 18.5 $82M NEW 2.3M 34.91
Keros Therapeutics (KROS) 12.3 $55M 1.4M 38.57
Kura Oncology (KURA) 9.0 $40M 1.3M 30.64
Alx Oncology Hldgs 8.3 $37M NEW 974k 37.74
Cytokinetics (CYTK) 8.2 $36M +4% 1.7M 21.65
Generation Bio (GBIO) 6.0 $27M 858k 30.91
Vaxcyte (PCVX) 5.2 $23M -24% 466k 49.38
Myokardia (MYOK) 3.9 $17M 127k 136.33
Cymabay Therapeutics (CBAY) 2.9 $13M -37% 1.8M 7.24
Arbutus Biopharma (ABUS) 2.4 $10M NEW 3.3M 3.13
Voyager Therapeutics (VYGR) 1.2 $5.5M 517k 10.67
Therapeutics Acquisition Corp Com Cl A 1.1 $5.0M NEW 350k 14.38
Panacea Acquisition Corp Unit 0.4 $1.8M NEW 150k 12.00

Setup an alert

Foresite Capital Management IV will file the next quarterly 13-HR in about 3 months. Would you like to be notified?

Aclaris Therapeutics (ACRS) 0.1 $372k NEW 145k 2.57

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017